Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

reldesemtiv

Biogen Idec building

Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

- PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease

Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy

- PMLiVE

Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

Biogen Idec building

Biogen’s Qalsody recommended by CHMP to treat rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all ALS cases

- PMLiVE

Innovate UK awards Sano Genetics £330,000 grant for ALS study

The project will chart the psychological impacts of having a genetic predisposition to ALS

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

- PMLiVE

Verge Genomics begins human trials with AI-sourced ALS drug

VRG50635 was discovered by the company’s all-in-human, AI-powered platform

- PMLiVE

Amylyx’s Relyvrio receives FDA approval for ALS treatment

Relyvrio was shown to significantly slow physical decline in people living with ALS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links